ProCE Banner Events


Advances in Hepatocellular and Biliary Tract Cancers Impacting Patient Outcomes

Join us for this dynamic CME/CE/CPE-certified live webinar, in which an expert panel will discuss current guidance and emerging strategies for treating patients with early and advanced HCC and biliary tract cancers. Sign up now!

Credits Available

Physicians: maximum of 1.50 AMA PRA Category 1 Credits

Physician Assistants: maximum of 1.50 hours of AAPA Category I (Preapproved) credits

Pharmacists: 1.50 contact hours (0.15 CEUs)

Registered Nurses: 1.50 Nursing contact hours

Who Should Attend

This educational program is intended for oncologists, physician assistants, nurses, pharmacists, and other healthcare professionals involved in the care of patients with hepatobiliary cancers. 

Time and location

Sunday, June 04, 2023

In-person | Virtual

7:00 PM - 8:30 PM Central Time (CT)

Hilton Chicago
720 South Michigan Avenue
Chicago, Illinois 60604

Salon A 2

Thomas A. Abrams, MD

Institute Physician
Director, Liver Tumor Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Stacey Stein, MD

Associate Professor of Medicine
Department of Medical Oncology
Yale University
Medical Oncologist
GI Oncology
Yale Cancer Center
New Haven, Connecticut

Mitesh Borad,


  • Introduction and Overview
  • First- and Second-line Systemic Therapy for Advanced HCC: Current and Emerging Immunotherapy Options
  • Immunotherapy Combinations for Early or Intermediate-Stage HCC: Current Evidence and Ongoing Trials
  • BTCs: Current and Emerging Immunotherapy and Targeted Therapy Regimens
  • Audience Q&A


Venue Name

Hilton Chicago


Hilton Chicago
720 South Michigan Avenue
Chicago, Illinois 60604

Room Name

Salon A 2


Target Audience
This educational program is intended for oncologists, physician assistants, nurses, pharmacists, and other healthcare professionals involved in the care of patients with hepatobiliary cancers. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Apply guidelines and expert recommendations for surveillance of patients at risk of developing hepatocellular carcinoma, including the clinical application of biomarker-based surveillance
  • Integrate clinical data and consensus guidelines on the use of systemic treatment approaches into practice for patients with early-stage or intermediate-stage HCC
  • Plan evidence-based and guideline-driven individualized care for patients with advanced HCC, both in the frontline and second-line treatment settings
  • Select optimal treatment for patients with cholangiocarcinoma and other BTCs based on molecular characterization of the tumor, previous treatment, and patient characteristics and preferences
  • Identify patients with HCC who may benefit from ongoing clinical trials based on tumor characteristics, previous treatment, and patient characteristics and preferences
  • Develop strategies to identify and mitigate unique adverse events associated with novel targeted therapies in patients with hepatobiliary cancers


Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

NCCN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
NCCN designates this educational activity for a maximum of 1.5 contact hours.

Continuing Pharmacy Education

NCCN designates this application-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credit. UAN: JA4008196-0000-23-035-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Attention Pharmacists:
You must complete the evaluation within 30 days of the activity for continuing pharmacy education credit to be reported to the CPE Monitor. Be sure to enter your NAPB e-profile ID and date of birth when prompted in the evaluation or your credit cannot be reported. If you have not already done so, please complete your e-profile at to obtain your NABP e-Profile ID.

Physician Assistants

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. 

Disclosure of Conflicts of Interest 
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose all financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships. In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. Full disclosure of faculty relationships will be made prior to the activity.


Provided by National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

Supported by an educational grant from AstraZeneca.

Program Learning Goal

Contact Information

Contact Clinical Care Options

For customer support please email:

Mailing Address:

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact prior to the live event.